Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
2 raisons identifiées
Auteur de référence en rhumatologie
27 articles scientifiques publiés — un praticien à la pointe de la recherche
Délais de RDV courts dans la région
86.1 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
ONCOPOP
CHP DE L'EUROPE 9 BIS AVENUE DE SAINT GERMAIN, 78560 LE PORT MARLY
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
European journal of preventive cardiology · 2026
Abstract Aims Identifying alternative contributors to the residual risk of atherosclerotic cardiovascular disease (ASCVD) beyond LDL cholesterol (LDL-C) levels is crucial. We investigated the relative impact of triglycerides (TGs) and high-sensitivity C-reactive protein (hs-CRP) on outcomes in statin-treated patients with well-controlled LDL-C undergoing percutaneous coronary intervention (PCI) for established ASCVD. Methods and results We included 9446 statin-treated patients with LDL-C < 70 mg/dL undergoing PCI between 2012 and 2022, stratified into four groups: (i) no residual risk (TG <150 mg/dL + hs-CRP <2 mg/L); (ii) residual TG risk (TG ≥150 mg/dL + hs-CRP <2 mg/L); (iii) residual inflammatory risk (TG <150 mg/dL + hs-CRP ≥2 mg/L); and (iv) residual TG and inflammatory risk (TG ≥150 mg/dL + hs-CRP ≥2 mg/L). The primary endpoint was major adverse cardiovascular events (MACE) at 1 year, consisting of all-cause mortality, myocardial infarction, or stroke. Cox regression analysis was performed, using the no residual risk group as a reference. Of the total population, 5339 (56.5%) had no residual risk, 555 (5.9%) presented residual TG risk, 3009 (31.9%) had residual inflammatory risk, and 543 (5.7%) exhibited residual combined risk. After multivariable adjustment, patients with residual inflammatory or combined risk showed a significantly higher hazard of MACE, mainly driven by all-cause mortality. No significant difference was observed between patients with residual TG risk and those with no residual risk. Conclusion In statin-treated patients with well-controlled LDL-C undergoing PCI, residual inflammatory risk—alone or in combination with residual TG risk—was associated with a higher incidence of MACE, highlighting the need for targeted preventive strategies beyond LDL-C lowering.
European heart journal · 2026
Abstract Background and Aims Dual antiplatelet therapy (DAPT) de-escalation strategies improve outcomes after percutaneous coronary intervention (PCI) compared to standard DAPT. However, the potential impact of sex on the safety and efficacy of these strategies is yet to be fully investigated. Methods Randomized controlled trials comparing de-escalated vs standard DAPT regimens in patients without baseline indication for oral anticoagulation reporting outcomes stratified by sex were included. The co-primary endpoints were trial-defined major adverse cardiovascular events (MACE) and major bleeding. Hazard ratios (HR) with 95% confidence intervals (CI) were computed to account for different follow-up durations. A network meta-analysis including ranking of treatments was performed to explore the comparative effects of different DAPT de-escalation strategies among females and males. Results Overall, 71 272 patients from 20 trials were included, and 23.3% were female. De-escalation strategies were grouped into (1) DAPT discontinuation, by aspirin or the P2Y12 inhibitor; or (2) P2Y12 inhibitor switch or dose reduction. With DAPT discontinuation vs standard DAPT, a significant interaction between treatment effect and sex was found for both MACE (Pint = .028) and major bleeding (Pint = .015). Indeed, DAPT discontinuation reduced MACE in females (HR, 0.86; 95% CI, 0.75–0.98) but not in males (HR, 1.04; 95% CI 0.93–1.16), while reducing major bleeding in males (HR, 0.60; 95% CI, 0.44–0.82) but not in females (HR, 1.04; 95% CI, 0.76–1.43), compared to standard DAPT. Conversely, no interactions by sex were found with P2Y12 inhibitor switch or dose reduction vs standard DAPT for both MACE (Pint = .668) and major bleeding (Pint = .858). At treatment ranking, aspirin discontinuation ranked best for most outcomes in females, while P2Y12 inhibitor switch to clopidogrel showed the best outcomes in males. Conclusions Sex may influence the safety and efficacy of antiplatelet de-escalation strategies after PCI, particularly those involving the shortening of DAPT. Aspirin discontinuation may represent the optimal strategy for females, while P2Y12 inhibitor switch to clopidogrel may be most effective for males.
Cardiovascular revascularization medicine : including molecular interventions · 2026
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
International journal of cardiology. Heart & vasculature · 2026 · Journal Article
Gadhe P, Sharma R, Farhan S, Song D, et al.
Annals of surgical oncology · 2026 · Journal Article
Deboever N, Khanduri I, Eisenberg M, Mehran RJ, et al.
The Journal of international medical research · 2026 · Journal Article
Been Sayeed SKJ, M M, Mahmud R, Rahman S, et al.
American heart journal · 2026 · Journal Article
Gouda P, Secemsky EA, Hess CN, Arya S, et al.
Journal of the American College of Cardiology · 2026 · Journal Article
Batchelor WB, Califf R, Mehran R, Stone G, et al.
Journal of the American College of Cardiology · 2026 · Journal Article
Cutlip DE, Mehran R, Sharma S, Doros G, et al.
JTCVS open · 2026 · Clinical Trial
Antonoff MB, Hooda Z, Sun X, Celestino M, et al.
JACC. Cardiovascular imaging · 2026 · Journal Article
Kini AS, Vengrenyuk Y, Liu J, Yasumura K, et al.
Cardiovascular revascularization medicine : including molecular interventions · 2026 · Journal Article
Roumeliotis A, Power D, Sartori S, Oliva A, et al.
Annals of thoracic surgery short reports · 2026 · Journal Article
Hooda Z, Ries S, Eisenberg M, Werner R, et al.
Journal of cardiac failure · 2026 · Journal Article
Jering KS, Claggett BL, Braunwald E, Granger CB, et al.
Physiotherapy · 2026 · Letter
Rashid FA, M RP
Nature medicine · 2026 · Published Erratum
Nicholls SJ, Nelson AJ, Ditmarsch M, Kastelein JJP, et al.
Annals of surgical oncology · 2026 · Journal Article
Folkert IW, Mehran R, Sun R, Morris VK, et al.
Drug development research · 2026 · Journal Article
Mehran MJ, Mohammadzadeh S, Bolideei M, Barzigar R, et al.
Clinical and experimental medicine · 2026 · Journal Article
Alshorman J, Mehran MJ, Bahrami Y, Mohammadzadeh S, et al.
Annals of surgical oncology · 2026 · Journal Article
Tomita K, Smith PM, Takayama M, Pan C, et al.
Annals of surgical oncology · 2026 · Journal Article
Tomita K, Smith PM, Takayama M, Pan C, et al.
European heart journal · 2026 · Journal Article
Occhipinti G, Laudani C, Galli M, Ortega-Paz L, et al.
Circulation · 2026 · Letter
Gragnano F, Giacoppo D, Choi KH, Kimura T, et al.
Atherosclerosis · 2026 · Journal Article
Hemelrijk KI, Delewi R, Mehran R, Boekholdt SM
JACC. Advances · 2026 · Journal Article
Michos ED, Saucier S, Mehran R, Koschinsky ML
The American journal of medicine · 2026 · Journal Article
Nardin M, Mehran R, Oliva A, Kedhi E, et al.
European journal of preventive cardiology · 2026 · Journal Article
Di Muro FM, Vogel B, Sartori S, Bay B, et al.
Atherosclerosis · 2026 · Journal Article
Hemelrijk KI, Delewi R, Mehran R, Boekholdt SM
EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology · 2026 · Journal Article
Raona V, Gitto M, Oliva A, Sartori S, et al.
The American journal of cardiology · 2026 · Journal Article
Pitaro NL, Zhang V, Sartori S, Smith KF, et al.
Nature medicine · 2026 · Journal Article
Nicholls SJ, Nelson AJ, Ditmarsch M, Kastelein JJP, et al.
Circulation · 2026 · Letter
Gragnano F, Giacoppo D, Choi KH, Kimura T, et al.